Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease

摘要: Background Drugs that mimic dopamine such as bromocriptine were introduced monotherapy or in a combination with LD the hope this approach would prevent delay onset of motor complications patients Parkinson's disease (PD). However, hitherto, role (BR) issue has remained controversial. The present study is systematic review all randomised controlled trials bromocriptine/levodopa (BR/LD) therapy compared levodopa (LD) PD. Objectives To assess efficacy and safety BR/LD delaying associated Search strategy Sources including Cochrane Library, search Movement Disorders Group (includes computerised searches MEDLINE EMBASE hand searching appropriate neurology journals), reference lists reviews found by search-strategy, Sandoz -now Novartis- (manufacturer BR), PPD Pharmaco, symposia reports, PD handbooks, contacts colleagues who had co-ordinated on BR included studies used to identify (RCTs) interest. Selection criteria Randomised eligible for inclusion if they evaluated patients. Outcome measures occurrence severity complications, scores impairment disability, side effects dropouts. Data collection analysis determine feasibility quantitative two independent reviewers methodological quality identified trials. Main results five showed important shortcomings. All failed adequately describe randomisation procedures. Only carried out according double-blind design. Differences between concerning mean age patients, titration phase, maximum achieved daily dose (62.5-1000 mg) (5-50 mg), applied outcomes found. Our show no evidence consistent differences disability both treatment groups. Reviewer's conclusions This support early